Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Vial Across Europe, to Treat Ophthalmic Conditions

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Optical

Health

Samsung Bioepis Co., Ltd.

More Like This

Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026

Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar